FLUMAZENIL ADMINISTRATION DURING ELECTROCONVULSIVE THERAPY: A RETROSPECTIVE CHART REVIEW ON EEG DURATION, SIDE EFFECTS AND CLINICAL OUTCOME

Nele Van de Velde¹, Lennart Gistelinck², Hannelore Tandt¹, Nele De Schryver¹ & Gilbert Lemmens¹

¹Department of Psychiatry, Ghent University Hospital, Ghent, Belgium
²Department of Psychiatry, General Hospital Sint-Jan Brugge-Oostende AV, Bruges, Belgium

Introduction: Benzodiazepines are considered to negatively affect seizure quality and duration during electroconvulsive therapy (ECT). Several researchers have advocated the use of flumazenil, a competitive benzodiazepine receptor antagonist, for patients receiving benzodiazepines during ECT treatment. However, clinical evidence regarding flumazenil use in ECT remains sparse. The aim of this study is to describe the effects of flumazenil on EEG seizure duration, clinical outcome and adverse effects.

Method: Twenty-six depressive and/or catatonic patients with concomitant benzodiazepine use receiving flumazenil during ECT were identified through retrospective chart review. Effects of flumazenil on depressive symptoms, catatonia, EEG duration and postictal agitation were assessed by the Inventory of Depressive Symptomatology, the Bush-Francis Catatonia Rating Scale and seizure duration on EEG. Postictal agitation was ascertained by identifying patients who received sedatives immediately after ECT or who needed physical restraint. The study was approved by the ethics committee of Ghent University Hospital.

Results: In patients receiving flumazenil, response and remission rates after ECT were 66.7% and 41.7% for depression and 91.7% and 75% for catatonia. Flumazenil administration increased EEG seizure duration with 10.5 seconds on average in patients comparing ECT with or without flumazenil administration and 58.3% of patients had an adequate seizure (> 15s). We found no correlation between benzodiazepine dose and seizure duration in patients receiving flumazenil before ECT. Postictal agitation occurred in 34.6% of the patients. One case of prolonged seizure, successfully managed with diazepam administration, was noted.

Conclusion: Patients with depression and/or catatonia and concomitant benzodiazepine use show good clinical outcome and increased EEG seizure duration after flumazenil treatment before ECT. However, postictal agitation seems to be a frequent and important side-effect. Current strategies to mitigate agitation should be considered when administering flumazenil.

* * * * *

PSYCHIATRIC SYMPTOMS IN PARKINSON DISEASE PATIENTS BEFORE AND AFTER ONE YEAR OF SUBTHALAMIC NUCLEUS DEEP BRAIN STIMULATION: ROLE OF LEAD POSITIONING AND TOTAL ELECTRICAL ENERGY DELIVERED

Giordano D’Urso¹, Teresa Somma², Antonio Scelzo¹, Sara Patti¹, Maria Rosaria Scala², Cinzia Baiano², Vincenzo Meglio², Felice Iasevoli¹, Luigi M. Cavallo², Domenico Solari², Andrea De Bartolomeis¹, Paolo Cappabianca² & Felice Esposito²

¹Department of Neurosciences and Reproductive and Dental Sciences, Division of Psychiatry, Università degli Studi di Napoli Federico II, Naples, Italy
²Department of Neurosciences and Reproductive and Dental Sciences, Division of Neurosurgery, Università degli Studi di Napoli Federico II, Naples, Italy

Introduction: Most patients with Parkinson’s disease (PD) experience psychiatric symptoms. Deep Brain Stimulation (DBS) is the most effective treatment for motor and non-motor symptoms of advanced PD. However, several studies hypothesized a possible correlation between DBS and the occurrence of mood disorders such as apathy, depression, and suicidal ideation. Additionally, conflicting results have been reported on the correlation between psychiatric symptoms and lead placement and total electrical energy delivered.

Methods: The study was performed at the University Federico II of Naples from 2011 to 2020. Fourteen patients (7 females, and 7 males) underwent a comprehensive psychopathological examination at baseline and after one year of STN-DBS. We assessed PD motor symptoms, depression, anxiety, apathy, impulsivity, and suicidality using clinical rating scales and correlated the results to the leads’ position using the Medtronic® Suretune™ software and to the total electrical energy delivered (TEED) according to the Koss formula.
<table>
<thead>
<tr>
<th>Case</th>
<th>Δ total UPDRS (%)</th>
<th>Δ HAM-D (%)</th>
<th>Δ BDI (%)</th>
<th>Δ HAM-A (C) (%)</th>
<th>Δ HAM-A (P) (%)</th>
<th>Δ BAI (%)</th>
<th>Δ AES (%)</th>
<th>Δ BIS-11 (A) (%)</th>
<th>Δ BIS-11 (M) (%)</th>
<th>Δ BIS-11 (NP) (%)</th>
<th>Δ RFL-48 (%)</th>
<th>Lead positioning left</th>
<th>right</th>
<th>TEED</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>-37.2</td>
<td>-60</td>
<td>-33.3</td>
<td>-58.8</td>
<td>-63.6</td>
<td>-50.0</td>
<td>-17.6</td>
<td>+33.3</td>
<td>+18.5</td>
<td>+16.7</td>
<td>+4.3</td>
<td>+33.3</td>
<td>/</td>
<td>+0.9</td>
</tr>
<tr>
<td>2</td>
<td>-6.1</td>
<td>-50</td>
<td>-73.3</td>
<td>-56.25</td>
<td>-64.5</td>
<td>-60.0</td>
<td>-50.0</td>
<td>-18.6</td>
<td>+18.6</td>
<td>+33.3</td>
<td>+13.6</td>
<td>+16.0</td>
<td>/</td>
<td>-14.5</td>
</tr>
<tr>
<td>3</td>
<td>-36.8</td>
<td>-109.1</td>
<td>-43.75</td>
<td>-16.7</td>
<td>+20.0</td>
<td>+42.9</td>
<td>+100</td>
<td>+85.0</td>
<td>-4.8</td>
<td>-6.7</td>
<td>-4.5</td>
<td>-17.1</td>
<td>M</td>
<td>C 0.0298</td>
</tr>
<tr>
<td>4</td>
<td>-48.9</td>
<td>-46.1</td>
<td>-50</td>
<td>-26.7</td>
<td>0</td>
<td>-57.1</td>
<td>-64.7</td>
<td>+10.0</td>
<td>+9.1</td>
<td>+37.5</td>
<td>-11.8</td>
<td>-13.6</td>
<td>/</td>
<td>-5.7</td>
</tr>
<tr>
<td>5</td>
<td>-37.2</td>
<td>-47.8</td>
<td>-27.8</td>
<td>-40.625</td>
<td>-30.0</td>
<td>-28.6</td>
<td>-30.3</td>
<td>+20.0</td>
<td>+9.7</td>
<td>+18.8</td>
<td>-15.8</td>
<td>0</td>
<td>/</td>
<td>-9.9</td>
</tr>
<tr>
<td>6</td>
<td>-48.6</td>
<td>-216.7</td>
<td>+100</td>
<td>+28.5</td>
<td>+140</td>
<td>-25.0</td>
<td>+100.0</td>
<td>+2.4</td>
<td>-4.1</td>
<td>-18.2</td>
<td>+33.3</td>
<td>-19.4</td>
<td>/</td>
<td>-13.9</td>
</tr>
<tr>
<td>7</td>
<td>-51.6</td>
<td>-57.1</td>
<td>-36.4</td>
<td>-10</td>
<td>0</td>
<td>-33.3</td>
<td>-90.0</td>
<td>-33.3</td>
<td>-1.6</td>
<td>-7.1</td>
<td>-7.4</td>
<td>/</td>
<td>+3.1</td>
<td>C</td>
</tr>
<tr>
<td>8</td>
<td>-38</td>
<td>/</td>
<td>-50.0</td>
<td>-33.3</td>
<td>-50.0</td>
<td>-57.1</td>
<td>-12.5</td>
<td>0</td>
<td>-9.5</td>
<td>-9.1</td>
<td>-8.9</td>
<td>/</td>
<td>-8.9</td>
<td>PL</td>
</tr>
<tr>
<td>9</td>
<td>-58.8</td>
<td>+18.2</td>
<td>+100</td>
<td>0</td>
<td>0</td>
<td>-16.7</td>
<td>-24.3</td>
<td>+46.3</td>
<td>+11.0</td>
<td>+73.3</td>
<td>+10.3</td>
<td>/</td>
<td>-12.2</td>
<td>L</td>
</tr>
<tr>
<td>10</td>
<td>-45.1</td>
<td>+500</td>
<td>-12.5</td>
<td>-240</td>
<td>-1000</td>
<td>-50.0</td>
<td>+45.5</td>
<td>+27.0</td>
<td>+45.3</td>
<td>+40.0</td>
<td>-23.8</td>
<td>+76.5</td>
<td>/</td>
<td>-16.6</td>
</tr>
<tr>
<td>11</td>
<td>-50.8</td>
<td>-46.7</td>
<td>-29.4</td>
<td>-23.0</td>
<td>-54.2</td>
<td>-16.7</td>
<td>+42.0</td>
<td>+33.3</td>
<td>+16.0</td>
<td>-18.8</td>
<td>/</td>
<td>-1.2</td>
<td>CA</td>
<td>PL</td>
</tr>
<tr>
<td>12</td>
<td>-59</td>
<td>-41.2</td>
<td>-12.5</td>
<td>-62.5</td>
<td>-61.5</td>
<td>-66.7</td>
<td>-56.3</td>
<td>+19.2</td>
<td>-16.4</td>
<td>-21.1</td>
<td>-41.2</td>
<td>-23.3</td>
<td>-100</td>
<td>+13.3</td>
</tr>
<tr>
<td>13</td>
<td>-37.2</td>
<td>-100</td>
<td>-89.5</td>
<td>-100</td>
<td>-100</td>
<td>-100</td>
<td>-53.8</td>
<td>-40.5</td>
<td>+27.9</td>
<td>+30.0</td>
<td>-43.8</td>
<td>+11.8</td>
<td>/</td>
<td>+22.9</td>
</tr>
<tr>
<td>14</td>
<td>-16.1</td>
<td>-16.7</td>
<td>-25.0</td>
<td>-52.9</td>
<td>-50</td>
<td>-57.1</td>
<td>-53.8</td>
<td>+22.7</td>
<td>+3.6</td>
<td>0</td>
<td>-30.4</td>
<td>+47.4</td>
<td>/</td>
<td>+10.2</td>
</tr>
</tbody>
</table>

Δ (delta): percentual difference between pre-operative and post-operative evaluation; PL: posterolateral; M: medial; C: central; CA: central anterior; LA: lateral anterior; P: posterior; MA: medial anterior; TEED: total electrical energy delivered.
**Results:** DBS induced a statistically significant improvement in motor symptoms (-38.5%, according to the Unified Parkinson's Disease Rating Scale part III), in anxiety (-29% according to the Hamilton Anxiety Rating Scale), with the strongest reduction in the physiological anxiety subscore (-36.26%). A mild worsening of impulsivity was detected at the Barratt Impulsiveness scale (+9%) with the greatest increase in the attentional impulsiveness subscore (+13.60%). No significant differences were found for the other scales. While the positioning of the stimulating electrodes was shown to considerably influence the outcome, with more anterior and/or medial lead position in the STN negatively influencing psychiatric symptoms, no correlation was found between TEED and clinical scales score (Table 1).

**Conclusions:** STN-DBS reduced anxiety and slightly increased impulsivity in PD patients after one year of DBS targeting the STN. While TEED did not correlate with any clinical scale score, leads’ placement significantly impacted on psychiatric symptoms.

**References:**

---

**THE EFFECTS OF TRANSCRANIAL DIRECT CURRENT STIMULATION ON EPISODIC FUTURE THINKING FOLLOWING ACUTE PSYCHOSOCIAL STRESS**

Linde De Wandel¹,², Stefanie De Smet¹,², Matias M. Pulopulos²,³, Gilbert Lemmens¹,⁴, Vanesa Hidalgo³,⁵, Alicia Salvador⁵, Marie-Anne Vanderhasse⁴, Jennifer E. Baeken¹,²,⁷,⁸

¹Department of Head and Skin - Psychiatry and Medical Psychology, Ghent University Hospital, Ghent, Belgium
²Ghent Experimental Psychiatry (GHEP) Lab, Ghent, Belgium
³Department of Psychology and Sociology, University of Zaragoza, Zaragoza, Spain
⁴Department of Psychiatry, Ghent University Hospital, Ghent, Belgium
⁵Department of Psychobiology, University of Valencia, Valencia, Spain
⁶Department of Psychology, University of Konstanz, Konstanz, Germany
⁷Department of Psychiatry, University Hospital UZBrussel, Brussels, Belgium
⁸Eindhoven University of Technology, Department of Electrical Engineering, Eindhoven, the Netherlands

**Introduction:** Research on stress-related disorders and brain imaging suggests that (acute) stress might impact the capacity to mentally simulate specific episodic future events (EFT) through the effects of cortisol on brain regions supporting this cognitive function, such as the prefrontal cortices. This study aims to examine the mechanisms underlying this link, using bifrontal transcranial Direct Current Stimulation (tDCS).

**Methods:** 60 healthy participants were subjected to the Montreal Imaging Stress Task (MIST), followed by either active or sham tDCS. After stimulation, the EFT task was administered. Salivary cortisol was measured throughout the protocol.

**Results:** Higher cortisol AUCi values were linked to less specific episodic future thoughts. Moreover, active tDCS enhanced EFT specificity irrespective of cortisol, especially in high trait ruminators. We did not observe an effect from active tDCS on cortisol AUCi, and equally there was no interaction effect between cortisol AUCi and stimulation condition predictive for EFT specificity.

**Conclusion:** Although we did not find evidence for the effects of tDCS on the HPA-system, our data reveal a crucial link between two critical predictors of mental health for the first time, and provide a solution to help rehabilitate EFT deficits.

**Keywords:** transcranial direct current stimulation - trait rumination - cortisol - Montreal Imaging Stress Task - episodic future thinking

**Funding:** This work was supported by a grant from the Neuromodulation call from the UZGent. This work was also supported by the ‘Fonds Wetenschappelijk Onderzoek’ [grant number 11J7521N].

**Acknowledgments:** We want to acknowledge the valuable contribution of MSc Elizabeth Se on conducting the testings, and Prof. Dr. Filip Raes and Dr. David Hallford for the procedure of the EFT task.